SmithKline Relafen Patent Ruling Clears Way For Trial In 2001
Executive Summary
Patent infringement litigation between SmithKline Beecham and generic companies seeking to launch versions of Relafen (nabumetone) will likely go to trial in the first half of 2001, the company said following an Aug. 16 summary judgment ruling.